Philip Bonomi is an Oncology physician affiliated with Rush University Medical Center. OpenAlex indexes 50 publications with 2,295 citations (h-index 16); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1725 W Harrison St
Suite 855
Chicago, IL 606123841
Telephone
312-942-5904Registry record last updated 8 Jul 2007.
Clinical trials
- A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
Sponsor: Cyclacel Pharmaceuticals, Inc.
- Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer
Sponsor: National Cancer Institute (NCI)
- Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML
Sponsor: Rush University Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20253 payments
- Helsinn Healthcare SAProgram year20232 payments$10,075openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20233 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
42.9%Serotonin-3 Receptor Antagonist16.4%Ondansetron Hcl100%Part D≥18 patientsCorticosteroid15.7%Prednisone100%Part D≥16 patients+ 1 more class in this area
Nervous system
25.7%Phenothiazine17.9%Prochlorperazine Maleate100%Part D≥19 patientsGabapentinoids7.9%Gabapentin100%Part D<11 patientsSensory organs
17.1%Corticosteroid17.1%Dexamethasone100%Part D≥21 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- P1.21 RNA Pathway Enrichment in Serum Based Mass Spectroscopy Prognostic Analyses
Journal of Thoracic Oncology
2019 - Bioinformatics Model of Serum Biomarkers to Prognosticate the Response to Programmed Death-1/Ligand-1 Targeted Immunotherapy in Metastatic Non–Small Cell Lung Cancer
American Journal of Clinical Pathology
2019 - Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer.
PubMed
2012
Similar KOLs
Other experts from the same institution or the same specialty.
Christopher Goetz, MD
Rush University Medical Center
Theodore Pincus, MD
Rush University Medical Center
Christopher Seder, MD
Rush University Medical Center
Melody Cobleigh, MD
Rush University Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”